S&P 500   4,585.59 (+0.80%)
DOW   36,117.38 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
S&P 500   4,585.59 (+0.80%)
DOW   36,117.38 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
S&P 500   4,585.59 (+0.80%)
DOW   36,117.38 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
S&P 500   4,585.59 (+0.80%)
DOW   36,117.38 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)

ProMetic Life Sciences Stock Price, News & Analysis (TSE:PLI)

Compare
Today's Range
N/A
50-Day Range
C$13.60
▼
C$13.60
52-Week Range
N/A
Volume
921 shs
Average Volume
8,002 shs
Market Capitalization
C$317.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PLI stock logo

About ProMetic Life Sciences Stock (TSE:PLI)

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.


PLI Stock News Headlines

July 24, 2023 | investing.com
TMC Life Sciences Bhd (TMCN)
February 21, 2023 | finance.yahoo.com
Arithmos appoints Maurizio Giraudo as Managing Director of the new Life Sciences Business Consulting Unit
December 7, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
July 31, 2021 | fool.ca
TSX:CVE (CENOVUS ENERGY INC.)
June 23, 2021 | markets.businessinsider.com
Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion
June 12, 2021 | marketwatch.com
Global Necrotic Enteritis Drug Market Research Report 2021 Size, Share, Growth, Trends and Forecast 2026 | COVID-19 Impact Analysis
May 25, 2021 | businesswire.com
NOXXON Announces Convocation of Its Hybrid 2021 Annual General Meeting of Shareholders
May 20, 2021 | msn.com
Drugmakers cry ‘monopoly’ as Modi govt picks 1 firm each to make over 20 key raw materials
December 7, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
May 20, 2021 | msn.com
People are more invested in preventive health, natural wellness than before: Sanjaya Mariwala, OmniActive Health Technologies
May 18, 2021 | msn.com
Animal Protein value chain is likely to grow in India in the next 5 -10 years: Balram Singh Yadav, Godrej Agrovet
May 6, 2021 | msn.com
India Reaches Out to US Companies Over Investment in Pharmaceutical, Medical Devices Sector
April 14, 2021 | benzinga.com
Greenberg Traurig's Bradley Jacobson to Speak at PLI's Private Placements and Hybrid Securities Offerings 2021 Virtual Conference
March 11, 2021 | marketwatch.com
Global Magnetic Separation Devices Market 2020 Analysis of Key Trend, Industry Dynamics and Future Growth 2025
February 5, 2021 | markets.businessinsider.com
Prometic Life Sciences Inc Registered Shs Stock , LMNL
February 5, 2021 | marketwatch.com
Idiopathic Pulmonary Fibrosis Market Size 2021 by Regional Production Volume, Opportunities, Revenue, Growth Rate and Forecast to 2025
January 27, 2021 | msn.com
Budget 2021: Focus on innovation, public health and manufacturing will be key
December 23, 2020 | marketwatch.com
Global Kidney (Renal) Fibrosis Market 2020 Industry Manufacturing Size, Share, Business Insights, Key Challenges and Forecast Analysis by 2025
November 18, 2020 | marketwatch.com
Global Kidney/Renal Fibrosis Treatment Market 2020 to 2026 - Top Manufacturers, Business Strategy and Forecast Report
November 5, 2020 | markets.businessinsider.com
Global Biopharmaceutical Bioseparation Systems Industry
October 2, 2020 | markets.businessinsider.com
Gamma Biosciences Acquires Nanopareil to Advance Next-Generation Purification Capabilities of Astrea Bioseparations
September 27, 2020 | marketwatch.com
Scleroderma Therapeutics Market Survey Report 2020 Along with Statistics, Forecasts till 2026
September 11, 2020 | marketwatch.com
Bioseparation System Market Global Outlook 2020 : 3M Company, Agilent Technologies, Waters Corporation
August 13, 2020 | marketwatch.com
Kidney (Renal) Fibrosis Market Research Report 2020-2026: By Product, Application, Manufacturer, Sales and Segmentation
August 8, 2020 | reuters.com
LMNL.OQ - Liminal BioSciences Inc Profile | Reuters
July 3, 2020 | www.marketwatch.com
Medical Waste Management Equipment Market Share and Growth Factors Impact Analysis 2020 - 2027
July 1, 2020 | www.marketwatch.com
Kidney/Renal Fibrosis Treatment MARKET | GLOBAL COVID-19 IMPACT ANALYSIS REPORT 2020 | GROWTH TRENDS AND INSIGHTS
See More Headlines
Receive PLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMetic Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:PLI
CUSIP
N/A
CIK
N/A
Web
prometic.com
Phone
+1-450-7810115
Fax
N/A
Employees
487
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
37.47
Current Ratio
4.06
Quick Ratio
3.66

Sales & Book Value

Annual Sales
C$39.91 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.94
Book Value
C$6.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
23,313,000
Free Float
N/A
Market Cap
C$317.06 million
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith (Age 56)
    CEO & Director
  • Mr. Bruce Pritchard
    International COO & Interim CFO
  • Mr. Patrick Sartore
    Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel (Age 65)
    Chief Bus. Devel. Officer
  • Dr. John Moran (Age 73)
    Chief Medical Officer

Key Competitors

View All Competitors














PLI Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ProMetic Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Dollarama (DOL), Parkland (PKI), Aurora Cannabis (ACB) and Resverlogix (RVX).

How do I buy shares of ProMetic Life Sciences?

Shares of PLI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:PLI) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -